阿普罗西坦:在高血压的药物治疗中,一个新的新兴前景
Lina Naseralallah1, Somaya Koraysh1
1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
Blood pressure
|November 9, 2024
概括
阿普罗西坦是一种新型内甲素受体抗剂,有效降低抗性高血压患者的血压. 虽然对治疗抗性高血压有希望,但需要进一步研究其对心血管和脏的长期影响.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 抗性高血压 (RH) 增加了心血管事件的风险,治疗选择有限.
- 作为一种常见的RH疗法,螺旋龙乳存在安全问题,限制了其使用.
- 阿普罗西坦是一种新型的双内甲素 (ET) A和B受体对抗剂,已被FDA批准用于RH.
研究的目的:
- 审查阿普罗西坦的发现,药理动力学,药理动力学,疗效和安全性,以治疗耐药高血压.
- 评估阿布罗西坦在解决RH管理中未得到满足的治疗需求中的作用.
主要方法:
- 在PubMed,Embase和国际制药摘要的系统文献搜索.
- 包括来自临床试验注册表的数据.
- 对阿布罗西坦的药理概况和临床证据进行了重点审查.
主要成果:
- 阿普罗西坦向ET通路,不受当前RH疗法的影响.
- 与其他ET受体对抗剂不同,阿布罗西坦对药物相互作用的风险较低.
- 临床试验表明,与安慰剂相比,阿布罗西坦能显著降低血压,常见的副作用是液体保留和贫血.
结论:
- 阿普罗西坦是一种新的,有效的治疗抗性高血压,显著降低血压.
- 这种药物提供了新的治疗前景,并增强了对RH病理生理学的理解.
- 目前缺乏关于心血管/脏保护和安全概况的长期数据.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153
Antihypertensive Drugs: Direct Renin Inhibitors
495
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
495
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
481
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
481


